Nasofan (Fluticasone Propionate)

Fluticasone Propionate, the active ingredient in Nasofan, is a corticosteroid presented as a nasal spray for nasal use. It reduces inflammation in the nasal passages and is indicated for conditions such as allergic rhinitis and nasal polyps.

GNH USA supplies Nasofan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Fluticasone Propionate is used in the management of inflammatory nasal disorders, acting on the mucosal immune response. - Allergic rhinitis: alleviates nasal congestion, itching and sneezing caused by allergens. - Seasonal allergic rhinitis: provides symptom relief during pollen seasons. - Nasal polyps: reduces polyp size and improves nasal airflow.

Fluticasone Propionate may cause local and systemic adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nasal irritation or burning sensation - Epistaxis (nosebleeds) - Headache - Altered taste or mouth dryness - Throat irritation - Cough

Serious or Rare Side Effects: - Adrenal suppression with prolonged high‑dose use - Cataracts or glaucoma development - Fungal infection of the nasal passages - Severe allergic reaction (anaphylaxis) - Nasal septal perforation - Vision changes requiring ophthalmologic evaluation

Before initiating therapy, consider patient‑specific factors and monitor for potential complications. - Assess for active nasal infection: avoid use until infection resolves. - Avoid in children under 2 years: safety not established. - Monitor for signs of adrenal suppression during long‑term therapy. - Use with caution in patients with glaucoma or cataracts. - Do not discontinue abruptly after prolonged use: taper as advised. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Fluticasone Propionate can interact with other medicines that affect corticosteroid metabolism or systemic exposure.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase systemic corticosteroid levels. - Ritonavir or other protease inhibitors: can elevate fluticasone exposure.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, phenytoin): may reduce efficacy. - Systemic corticosteroids: additive systemic effects. - Antifungal agents (e.g., fluconazole): may modestly increase exposure.